Doctor of Osteopathy Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Gerald Harris

Addiction Medicine Peoria, AZ Doctor of Osteopathy

NPI 1689676165 CMS profile 76961

8914 N 91St Ave Ste 100A, Peoria, AZ 85345

Open in the dashboard

General payments

$5,045

229 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Gerald Harris of Peoria, AZ is reported in the CMS Open Payments database as having received $5,045 across 229 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,543 54
2021 General $1,191 63
2020 General $793 40
2019 General $1,518 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gerald Harris
  • Addiction Medicine median
  • Middle half of Addiction Medicine
  • National median

In program year 2025, general payments to Gerald Harris were reported at $0. Among 183 Addiction Medicine profiles paid that year, the median was $124 and the middle half received between $43 and $384.

Show as a table
Year Gerald Harris Addiction Medicine median Middle half National median
2019 $1,518 $115 $34–$328 $163
2020 $793 $64 $22–$259 $114
2021 $1,191 $97 $25–$267 $132
2022 $1,543 $70 $25–$255 $149
2023 $0 $105 $29–$270 $160
2024 $0 $122 $39–$378 $164
2025 $0 $124 $43–$384 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AstraZeneca Pharmaceuticals LP $836 29 payments
  2. Indivior Inc. $472 20 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $439 19 payments
  4. Medtronic, Inc. $361 6 payments
  5. US WorldMeds, LLC $325 26 payments
  6. Orexo US, Inc. $321 24 payments
  7. Antares Pharma, Inc. $317 32 payments
  8. Lucid Diagnostics Inc. $300 8 payments
  9. AbbVie, Inc. $292 8 payments
  10. Novo Nordisk Inc $246 9 payments
  11. Other $1,136 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $5,044 228 payments
  2. Education $1 1 payment
Products named General payments · program years 2019–2022
  1. FARXIGA $778 26 payments
  2. SUBLOCADE $417 17 payments
  3. MINIMED 770G $342 4 payments
  4. XIFAXAN $318 18 payments
  5. Zubsolv $291 22 payments
  6. Lucemyra/Lofexidine $226 20 payments
  7. Ozempic $198 6 payments
  8. XYOSTED $173 19 payments
  9. TRULANCE $151 4 payments
  10. NOCDURNA $144 13 payments
  11. Other $2,160 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

229 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record